Biocon Q3 PAT seen up 10% to Rs 94 cr QoQ

Pharmaceutical firm Biocon is likely to post a profit after tax of Rs 94 crore in the third quarter of FY12, a growth of 10% as compared to Rs 86 crore in the previous quarter.

January 24, 2012 / 09:14 IST

26 Aug, 2025 12:21

Volume

Todays L/H

Pharmaceutical firm Biocon is likely to post a profit after tax of Rs 94 crore in the third quarter of FY12, a growth of 10% as compared to Rs 86 crore in the previous quarter.

Revenues are seen going up by 7% to Rs 552 crore from Rs 513 crore quarter-on-quarter.

EBITDA is expected to go up by 10% to Rs 152 crore in the quarter ended December FY12 versus Rs 138.5 crore in the previous quarter.

Operating profit margin is likely to be at 27.6% versus 27% during the same period.

Watch out for:

- Growth to be led by Biopharm + CRAMS

- In Q2 Biopharma grew 21% led by Statins, Immunosuppresants, Insulin + Fidaxomicin API to Optimer and within Branded formulations growth was led by diabetology which grew 46% YoY

-CRAMS has picked up

first published: Jan 24, 2012 09:13 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

Al Edge Newsletter On Saturdays

Find the best of Al News in one place, specially curated for you every weekend.
MC Tech 3 Newsletter Daily-Weekdays

Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347